BRCA-related breast carcinoma can be prevented through prophylactic surgery and an intensive follow-up regimen. However, BRCA genetic tests cannot be routinely performed, and some BRCA mutations could not be defined as deleterious mutations or normal variants. Therefore, an easy functional assay of BRCA will be useful to evaluate BRCA status. As it has been reported that BRCA functions in the regulation of centrosome number, we focused on centrosome number in cancer tissues. Here, 70 breast cancer specimens with known BRCA status were analyzed using immunofluorescence of c-tubulin (a marker of centrosome) foci. The number of foci per cell was higher in cases with BRCA mutation compared to wild-type cases, that is, 1.9 (95% confidence interval [CI], 1.5-2.3) vs 0.5 (95% CI, 0.2-0.8) (P < .001).
and have problems associated with privacy and genetic counseling.
Furthermore, some BRCA mutations could not be defined as deleterious mutations or normal variants, and thus, are treated as a variant of unknown significance (VUS). It is therefore important to devise an inexpensive and simple test for predicting BRCA mutation status; functional evaluation of the BRCA protein is particularly desired.
Many risk estimation tools for detecting deleterious BRCA mutations based on clinicopathological information have been reported, such as BRCAPRO, 5, 6 Myriad Table, 7 and the Korean Hereditary Breast Cancer BRCA risk calculator (KOHCal). 8 However, factors such as small family size or a small number of female relatives can prevent accurate assessment of risk. 9 In this study, we focused on another BRCA function, controlling centrosome duplication; [10] [11] [12] it is known that BRCA plays important roles in the DNA repair pathway. Cells normally have either one or two centrosomes. Suppression of BRCA1 or BRCA2 causes centrosome amplification. 13, 14 We therefore speculated that an increase in the number of centrosomes may indicate BRCA mutations in breast cancer specimens. c-Tubulin, a centrosome component, could not be detected as foci by immunohistochemistry using 3,3-diaminobenzidine (DAB), 15 whereas immunofluorescence of c-tubulin was detected as foci in mammalian cells 12 and human breast tissue. 16, 17 We used this latter approach in the present study to determine whether the number of c-tubulin foci could predict BRCA status in clinical samples.
| MATERIALS AND METHODS

| Patients
From 2001 to 2014, 68 female Japanese breast cancer patients (including two patients with bilateral breast cancer) underwent breast cancer surgery and genetic testing for BRCA mutations at Hoshi General Hospital (Fukushima, Japan) and Ishinomaki Red Cross Hospital (Ishinomaki, Japan). In both hospitals, patients who met the criteria for BRCA1/2 testing according to the National Comprehensive Cancer Network (NCCN) guidelines were recommended to undergo genetic testing; however, the testing was not covered by Japanese national health insurance. One patient who did not meet the NCCN guidelines underwent genetic testing because of her desire to be tested. All participants were interviewed by experienced genetic counselors to determine the personal and family history of cancer (at least first-and second-degree relatives). The study protocol was approved by the institutional review board at each institution and at Tohoku University Graduate School of Medicine (Sendai, Japan).
| Mutation detection
Genomic DNA samples from study subjects at Hoshi General Hospital and Ishinomaki Red Cross Hospital were analyzed at Myriad
Genetic Laboratories (Salt Lake City, UT, USA). Full sequencing analysis was carried out for probands, and single-site testing for the family-specific mutations (seven patients) was undertaken for relatives of mutation-positive probands.
2.3 | Estimation of BRCA1/2 mutation probability using available prediction models, BRCAPRO, Myriad Tables, and KOHCal Our analysis of the predictive value of BRCA status compared to pretests was restricted to patients who did not have a family history of deleterious BRCA mutations, as seven patients who had such a history were likely to have undergone BRCA genetic testing. One patient was excluded from the analysis because of sufficient familial history.
The BRCAPRO model calculated the probability of a BRCA1 and/ or BRCA2 mutation from patients' personal and first-and seconddegree relatives' history of breast and ovarian cancers. 5, 6 We used the version implemented in the BayesMendel 2. Nichirei Bioscience, Tokyo, Japan) for DAB staining for 1 hour at room temperature. Nuclei were stained with DAPI (Vector Laboratories, Burlingame, CA, USA).
| Microscopy
The number of c-tubulin foci per cell was counted using a BZ9000
all-in-one fluorescence microscope (Keyence, Osaka, Japan) with an integrated camera and BZ-Analyzer software (Keyence). Foci were counted with Hybrid Cell Counter software in nine to 12 visual fields at 1009 magnification. c-Tubulin foci were captured from 10 lower to higher depth fields with a 0.4-lm pitch for Z-axis scanning. Composite images were generated with the image-joining function of the software and Z-axis data were extracted at a single focal point from multiplane images to obtain a fully focused image using the quick full-focusing function of the software. 
| Statistical analysis
The relationship between clinicopathological parameters and BRCA respectively. All of the areas of the foci/cell number were higher for BRCA1 L63X (foci/cell = 1.10, Figure 1H ) and BRCA2 2423del4
(foci/cell = 6.52; Figure 1M ) compared to wild-type BRCA (foci/ cell = 0.53; Figure 1C ).
As shown in Figure 2 , the number of c-tubulin foci/cell was higher in cases with BRCA1 and/or BRCA2 mutation than in wildtype BRCA1 and BRCA2 (1.9 [95% confidence interval (CI), 1. (95% CI, 1.7-2.6), respectively, which was higher than that for wildtype BRCA1 and BRCA2 (P = .042 and P < .0001, respectively).
As shown in Figure 3 BRCA mutations. c-Tubulin immunofluorescence had superior predictive value (P < .0001), followed by BRCAPRO (P = .0073) ( Table 2) .
We next analyzed ROC curves to determine the appropriate cutoff point for predicting BRCA mutation status (Figure 4 ). c-Tubulin immunofluorescence had the highest AUC (0.86; Figure 4D ). The AUC (0.97; Figure 4F ) of the BRCA2 mutation was higher than that of the BRCA1 mutation (0.79; Figure 4E ). 
| DISCUSSION
The ability to identify BRCA-related cancer patients among many breast cancer patients is important, because these patients are suitable for targeted therapy and prophylactic surgery as well as intensive follow-up to prevent breast cancer-related death. 9, 24, 25 These pretests that use clinicopathological information might be more affected by ethnic differences than our method. 26 The immunohistochemical analysis of breast cancer specimens, especially of estrogen receptor and human epidermal growth factor receptor 2 expression, is important for determining the appropriate treatment by targeted therapy. These overexpressed proteins are easy to evaluate by immunohistochemistry; on the contrary, evaluation of tumor suppressor proteins such as p53 and BRCA is challenging. We previously focused on protein function to determine gene status by immunohistochemistry, and have reported combined immunohistochemical detection of p53 and its downstream proteins for predicting TP53 mutation. 27 Shimomura et al reported that loss of BRCA1 expression was associated with an increase in the number Tumors with the molecular features of BRCA mutation are known as having "BRCAness". 28 BRCAness is not only the inactivation of a protein related to DNA repair pathways, but also methylation of BRCA1 or BRCA2. 29 The Cancer Genome Atlas study showed 60% of basal-like breast cancers involved BRCA inactivation, including methylation and mutation. 2 BRCAness evaluation is important for determining individualized treatment regimens that can include PARP inhibitors or DNA cross-linking agents. Several studies have attempted to identify BRCAness using transcriptional biomarkers 30, 31 or by assaying homologous recombination. 32, 33 The homologous recombination deficiency score is highly correlated with defects in BRCA1/2 and is associated with the response to platinum therapy, Including one normal variant (BRCA1 G275D) and two intronic mutation patients.
but this scoring system is complex. In this study, some cases of increased centrosome number in BRCA wild-type individuals (23% of false-positive results) might be considered to represent BRCAness.
Centrosome amplification often occurs in human cancers, especially in breast cancer. 34 Triple negative breast cancers strongly correlate with centrosomal amplification using immunofluorescence analysis of c-tubulin, the same as our method. 35, 36 Based on their biological functions, both BRCA1 and BRCA2 play important roles in the proper control of centrosome duplication: BRCA1 is a ubiquitin ligase of c-tubulin that regulates centrosome number; 13 and BRCA2 has a centrosomal localization signal that functions in centrosome positioning, amplification, and cohesion. [37] [38] [39] Numerous studies have revealed that inhibition of BRCA function causes centrosome aberrations in human breast cell lines, mice, and human breast tissue. 13, 17, 40 However, many proteins function to control centrosome duplications. 41 Therefore, the 23% false-positive rate in our study may involve disruption of other centrosomal proteins.
There is a debate as to whether all deleterious mutations of BRCA1/2 genes equally disrupt both functions: controlling centrosome duplication and homologous recombination. 42 We and Cochran et al have reported that most BRCA deleterious mutations abrogate centrosome duplication and are well correlated with DNA repair function (Table S2) . 8, 10, 43 However, the 17% false-negative rate in our study might retain controlling centrosome duplication with BRCA mutation.
Our study has two limitations. First, although the foci/cell were counted using an objective evaluation method and two previous reports support an increased number of specimens with BRCA mutations among breast cancer specimens, 16, 17 our findings need to be validated by additional data. Second, centrosomes are regulated by multiple factors, including BRCA1/2. 11 We need to investigate the other factors that contribute to increased centrosome number with wild-type BRCA.
In conclusion, an increased number of centrosomes can be used to predict the presence of BRCA mutation, thus potentially assisting patients in deciding whether to pursue genetic testing.
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